the American multinational pharmaceutical corporation Pfizer (NYSE: PFE) logo seen displayed on a smartphone with an economic stock exchange index graph in the background. (Budrul Chukrut/SOPA ...

The 10-second video shows the rapper playing with a football and an ending tag, “See you at the game,” with the Pfizer logo. Additional teasers will be posted Saturday and Sunday mornings ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company’s adjusted EPS of 63 cents beat Wall Street’s estimate of 47 cents ...

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The company’s shares opened today at $26.10. Leverage the power ...

BMO Capital markets analyst Evan Seigerman said Pfizer's forecast is already conservative, and with COVID products no longer seen as a core business, investor reaction to lower volumes could be muted.

Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, chief investor relations officer and senior vice president. Please go ahead, ma'am.Francesca ...

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 ...

Pfizer appears to fall into that opportunistic category. That makes the stock a buy for any investor looking for reliable dividend income, or just a good deal today. Justin Pope has no position in ...

However, at least two conditions listed as adverse events also appeared in Pfizer's 2024 list of genuine side effects. In January 2025, Snopes readers asked us about the authenticity of a long ...

Three students from Centreville High School in Clifton discovered a potentially harmful substance – DNA residues, or tiny fragments of genetic material – in Pfizer’s messenger RNA COVID-19 ...

But soon the Obama administration came down hard on such 'tax inversion' deals, changing laws such that the deal was no longer attractive to Pfizer. No signs of slowing down Despite some setbacks ...